

## **Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients**

Nicolò Compagno, Francesco Cinetto, Gianpietro Semenzato and Carlo Agostini

Department of Medicine, Hematology and Clinical Immunology Branch, Padova University School of Medicine, Italy

---

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.101261

Manuscript received on November 26, 2013. Manuscript accepted on March 18, 2014.

Correspondence: [carlo.agostini@unipd.it](mailto:carlo.agostini@unipd.it)

## Quality of life questionnaire

**1) During IVIg replacement therapy how much did infectious events interfere with your normal work (including both work outside the home and housework)?**

Not at all  
A little bit  
Moderately  
Quite a bit  
Extremely

**2) During SCIg replacement therapy how much did infectious events interfere with your normal work (including both work outside the home and housework)?**

Not at all  
A little bit  
Moderately  
Quite a bit  
Extremely

**3) Compared to IVIg replacement therapy, how would you rate your health relating to infectious events with SCIg replacement therapy?**

Much better with SCIg than with IVIg  
Somewhat better with SCIg than with IVIg  
About the same  
Somewhat worse with SCIg than with IVIg  
Much worse with SCIg than with IVIg

**4) During IVIg replacement therapy how much did adverse events of replacement therapy interfere with your normal work (including both work outside the home and housework)?**

Not at all  
A little bit  
Moderately  
Quite a bit  
Extremely

**5) During SCIg replacement therapy how much did adverse events of replacement therapy interfere with your normal work (including both work outside the home and housework)?**

Not at all  
A little bit  
Moderately  
Quite a bit  
Extremely

**6) Compared to IVIg replacement therapy, how would you rate your health relating to adverse events of replacement therapy with SCIg replacement therapy?**

Much better with SCIg than with IVIg  
Somewhat better with SCIg than with IVIg  
About the same  
Somewhat worse with SCIg than with IVIg  
Much worse with SCIg than with IVIg

**7) How do you rate the possibility of home infusion of SCIg instead of hospital-infusion of IVIg?**

Much better with SCIg than with IVIg  
Somewhat better with SCIg than with IVIg  
About the same  
Somewhat worse with SCIg than with IVIg  
Much worse with SCIg than with IVIg

**8) Considering all these aspects (infectious events, adverse events, home-infusion) how do you rate the impact of SCIg replacement therapy instead of IVIg replacement therapy in your health?**


Much better with SCIg than with IVIg  
Somewhat better with SCIg than with IVIg  
About the same  
Somewhat worse with SCIg than with IVIg  
Much worse with SCIg than with IVIg

## Quality of life analysis


Analysis of the quality of life questionnaire, administered to the 33 patients shifted from IVIg to SCIg.

Y axis: absolute number


**1) During IVIg replacement therapy how much did infectious events interfere with your normal work (including both work outside the home and housework)?**




**2) During SCIg replacement therapy how much did infectious events interfere with your normal work (including both work outside the home and housework)?**




**3) Compared to IVIg replacement therapy, how would you rate your health relating to infectious events with SCIg replacement therapy?**




**4) During IVIg replacement therapy how much did adverse events of replacement therapy interfere with your normal work (including both work outside the home and housework)?**




**5) During SCIg replacement therapy how much did adverse events of replacement therapy interfere with your normal work (including both work outside the home and housework)?**



**6) Compared to IVIg replacement therapy, how would you rate your health relating to adverse events of replacement therapy with SCIg replacement therapy?**



**7) How do you rate the possibility of home infusion of SCIg instead of hospital-infusion of IVIg?**



**8) Considering all these aspects (infectious events, adverse events, home-infusion) how do you rate the impact of SCIg replacement therapy instead of IVIg replacement therapy in your health?**

